Key Points
- Melissa Epperly, a Roivant director, sold 41,861 shares on March 16 at an average price of $28.68 for total proceeds of $1,200,573.48, cutting her holding by 72.59% to 15,804 shares valued at about $453,259.
- Roivant trades near recent highs (opened $27.80; 52‑week range $8.73–$30.33) and has mixed analyst sentiment but a consensus "Moderate Buy" with an average target of $28.81 after several firms raised targets while Weiss Ratings downgraded to a "sell".
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) Director Melissa Epperly sold 41,861 shares of Roivant Sciences stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $28.68, for a total transaction of $1,200,573.48. Following the transaction, the director directly owned 15,804 shares in the company, valued at $453,258.72. The trade was a 72.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Roivant Sciences Stock Performance
Shares of NASDAQ:ROIV opened at $27.80 on Thursday. The company has a 50 day moving average price of $25.68 and a two-hundred day moving average price of $21.04. The company has a market capitalization of $19.90 billion, a PE ratio of -23.76 and a beta of 1.17. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $30.33.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on the company. HC Wainwright lifted their target price on Roivant Sciences from $33.00 to $34.00 and gave the stock a "buy" rating in a report on Wednesday, March 4th. TD Cowen restated a "buy" rating on shares of Roivant Sciences in a report on Wednesday, March 4th. Leerink Partners raised their price target on Roivant Sciences from $29.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, December 15th. Weiss Ratings cut Roivant Sciences from a "hold (c-)" rating to a "sell (d)" rating in a report on Monday, February 9th. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Roivant Sciences currently has an average rating of "Moderate Buy" and an average target price of $28.81.
Check Out Our Latest Report on Roivant Sciences
Hedge Funds Weigh In On Roivant Sciences
A number of large investors have recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund lifted its holdings in shares of Roivant Sciences by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company's stock valued at $1,891,000 after purchasing an additional 500 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Roivant Sciences by 1.3% during the fourth quarter. Bank of Montreal Can now owns 40,012 shares of the company's stock worth $868,000 after buying an additional 516 shares in the last quarter. Bessemer Group Inc. grew its holdings in shares of Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock worth $28,000 after buying an additional 543 shares in the last quarter. Allworth Financial LP raised its position in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company's stock valued at $27,000 after buying an additional 583 shares during the last quarter. Finally, Fifth Third Bancorp lifted its stake in Roivant Sciences by 15.8% in the 4th quarter. Fifth Third Bancorp now owns 4,310 shares of the company's stock valued at $94,000 after acquiring an additional 588 shares in the last quarter. Institutional investors own 64.76% of the company's stock.
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
